<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395055</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-057-1</org_study_id>
    <nct_id>NCT02395055</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Trial to Evaluate Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers</brief_title>
  <official_title>Single Center Comparative Double Blind Randomized Clinical Study of Pharmacokinetics, Tolerance and Safety of Single Subcutaneous Injection of BCD-057 (JSC &quot;BIOCAD&quot;, Russia) and Humira in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a phase 1 study which carried out to establish the pharmacokinetic
      equivalence and equal safety and tolerability profile of BCD-057 (adalimumab biosimilar
      candidate manufactured by CJSC BIOCAD, Russia) and Humira when used as a single subcutaneous
      injection in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is single center comparative double blind randomized clinical study of pharmacokinetics,
      tolerance and safety of single subcutaneous injection of BCD-057 (CJSC BIOCAD, Russia) and
      Humira in healthy volunteers. The purpose of the study is to demonstrate that BCD-057 is
      equivalent to Humira in terms of pharmacokinetics, tolerability and safety after single
      subcutaneous injection in healthy volunteers.

      The study will enroll 94 healthy volunteers, who will be randomized into 2 groups (1:1
      ratio): volunteers from the first group will receive BCD-057; volunteers from the second
      group will receive Humira. Both study and reference drug will be used at the standard dose of
      40 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira</measure>
    <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity</measure>
    <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.</measure>
    <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCD-057 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab (BCD-057)</intervention_name>
    <description>Adalimumab is a monoclonal antibody against tumor necrosis factor alpha</description>
    <arm_group_label>BCD-057 group</arm_group_label>
    <other_name>BCD-057</other_name>
    <other_name>Humira</other_name>
    <other_name>Trudexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab (Humira)</intervention_name>
    <description>Adalimumab is a monoclonal antibody against tumor necrosis factor alpha</description>
    <arm_group_label>Humira group</arm_group_label>
    <other_name>Trudexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has provided informed consent;

          -  male gender;

          -  18 - 45 years of age inclusively;

          -  a body mass index (BMI) between 18,5 and 30 kg/m2;

          -  absence of clinically significant hepatic, renal, gastrointestinal, cardiovascular,
             endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic
             abnormality at screening or/and in anamnesis;

          -  parameters of complete blood count, blood biochemistry and urinalysis do not exceed
             reference values, which are used at Study site laboratory. Evaluation of required
             laboratory parameters must be performed within 14 days before randomization;

          -  normal hemodynamic parameters: systolic BP 100 - 139 mm Hg, diastolic BP - 60 - 90 mm
             Hg, heart rate - 60 - 90 b/min;

          -  ECG results are normal for this age group;

          -  absence of chronic infections (HIV, syphilis, hepatitis В or С) and chronic
             inflammation;

          -  absence of active or latent tuberculosis;

          -  absence of infections within 4 weeks before randomization;

          -  absence of mental disorders or other conditions, which may affect the ability of
             participant to follow Protocol;

          -  health well-being (by volunteer's opinion) for at least 30 days before randomization;

          -  ability to follow Protocol procedures;

          -  consent of volunteers and their sexual partners with childbearing potential to use
             adequate contraception during screening period and the main study part;

          -  absence of alcohol or drug addiction signs (incl. history of such addiction);

          -  consent not to consume alcohol within 24 hours before SC injection of BCD-057/Humira
             and not to use more than 10 units of alcohol per week during the study (1 alcohol unit
             is equal ½ l of beer (1 pint), or 200 ml of wine, or 50 ml alcohol)

        Exclusion Criteria:

          -  history of adalimumab use or any other TNF inhibitors;

          -  known severe allergy (anaphylaxis or multidrug intolerance);

          -  known intolerance of monoclonal antibodies or any other excipients of BCD-057/Humira;

          -  major surgery within 30 days before ICF signing;

          -  presence of clinically significant hepatic, renal, gastrointestinal, cardiovascular,
             endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic
             abnormality at screening or/and in anamnesis.

          -  infections which required hospitalization, parenteral anti-infectives within 6 months
             before randomization;

          -  positive results of tests for HIV-1 and HIV-2 antibodies, positive Hbs-Ag, HBc IgM,
             total antibodies against HCV, positive results of RPR-test;

          -  more than 4 episodes of acute respiratory infection within 6 months before
             randomization;

          -  any malignancy (present or history);

          -  tuberculosis, including latent forms;

          -  shingles (present or history).

          -  history of seizures;

          -  any disorders or other conditions, which may affect pharmacokinetics of BCD-057/Humira
             (e.g. chronic liver diseases, chronic kidney diseases, cardiovascular disorders, lung
             disorders, endocrine diseases, etc.).

          -  use of systemic antimicrobial or antifungal medicines within 2 months before
             randomization;

          -  regular oral or parenteral use of any medicines, vitamins, biologically active
             additives within two weeks before signing of ICF;

          -  any use of medicines, vitamins, biologically active additives within 30 days before
             signing of ICF;

          -  use of medicines, which may influence on immunity within 30 days before signing of
             ICF;

          -  vaccination within 4 weeks prior randomization;

          -  smoking of more than 10 cigarettes per day;

          -  use of alcohol, which exceeds 10 units per week (1 alcohol unit is equal ½ l of beer
             (1 pint), or 200 ml of vine, or 50 ml alcohol). History of alcohol or drug addiction;

          -  donation of more than 450 ml of blood or plasma within 2 months prior randomization;

          -  simultaneous participation in any other clinical trial, as well as former
             participation in other clinical trials within 3 months before this study initiation;

          -  previous participation in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>CJCS BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LLC BioEk</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>March 31, 2016</results_first_submitted>
  <results_first_submitted_qc>April 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-057 Group</title>
          <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
        <group group_id="P2">
          <title>Humira Group</title>
          <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population for all type of analysis included 84 patients who received at least one study drug injection.</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-057 Group</title>
          <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
        <group group_id="B2">
          <title>Humira Group</title>
          <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" lower_limit="22" upper_limit="30.5"/>
                    <measurement group_id="B2" value="25.5" lower_limit="22" upper_limit="29"/>
                    <measurement group_id="B3" value="25" lower_limit="22" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira</title>
        <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
        <population>All patients who received one injection of adalimumab.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-057 Group</title>
            <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
          <group group_id="O2">
            <title>Humira Group</title>
            <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira</title>
          <population>All patients who received one injection of adalimumab.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4426" lower_limit="3524" upper_limit="5902"/>
                    <measurement group_id="O2" value="4522" lower_limit="3546" upper_limit="5104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity</title>
        <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
        <population>All patients who received adalimumab injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-057 Group</title>
            <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
          <group group_id="O2">
            <title>Humira Group</title>
            <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity</title>
          <population>All patients who received adalimumab injection.</population>
          <units>(ng/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2488188" lower_limit="1809194" upper_limit="2827564"/>
                    <measurement group_id="O2" value="2272029" lower_limit="1815831" upper_limit="2904679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.</title>
        <time_frame>0, 6, 24, 48, 72, 96, 120, 144, 168, 192, 336, 672, 1008, 1440, 1680 hours post-dose</time_frame>
        <population>All volunteers who received one adalimumab injection.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-057 Group</title>
            <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
          <group group_id="O2">
            <title>Humira Group</title>
            <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.</title>
          <population>All volunteers who received one adalimumab injection.</population>
          <units>(ng/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2488187" lower_limit="1809193" upper_limit="2778993"/>
                    <measurement group_id="O2" value="2272029" lower_limit="1815831" upper_limit="2858812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>70 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-057 Group</title>
          <description>BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
        <group group_id="E2">
          <title>Humira Group</title>
          <description>Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Monocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biryulin Andrey</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7812380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

